REDUCTION OF LDL CHOLESTEROL BY PRAVASTATIN DOES NOT INFLUENCE PLATELET ACTIVATION IN PATIENTS WITH MILD HYPERCHOLESTEROLEMIA AT RISK OF CORONARY HEART-DISEASE

被引：17
|
作者：
BARROW, SE [1 ]
STRATTON, PD [1 ]
BENJAMIN, N [1 ]
BRASSFIELD, T [1 ]
RITTER, JM [1 ]
机构：
[1] BRISTOL MYERS SQUIBB PHARMACEUT,CLIN RES DEPT,HOUNSLOW TW3 3JA,MIDDX,ENGLAND
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 1991年 / 32卷 / 01期
关键词：
THROMBOXANE A2; PLATELET ACTIVATION; PRAVASTATIN; LDL; HYPERCHOLESTEROLEMIA;
D O I：
10.1111/j.1365-2125.1991.tb05625.x
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The effect of pravastatin on low density lipoprotein (LDL) cholesterol and platelet activation was studied in 16 patients with mild hypercholesterolaemia who had two or more additional cardiovascular risk factors. Patients were treated with either pravastatin (20-40 mg day-1) or placebo for 1 year. Plasma LDL and urinary excretion of 2,3-dinor-thromboxane B2 (an index of platelet activation in vivo) were determined at 0, 3, 6 and 12 months. There was a significant reduction in LDL at 6 and 12 months (2P < 0.05) but this was not associated with any significant change in thromboxane metabolite excretion.
引用
收藏
页码：127 / 129
页数：3
相关论文
共 27 条
  • [1] Electrocardiographic events and cholesterol reduction with pravastatin in patients with hypercholesterolemia: The Hokuriku Lipid Coronary Heart Disease Study-Pravastatin Atherosclerosis Trial
    Shimizu, M
    Koizumi, J
    Miyamoto, S
    Origasa, H
    Mabuchi, H
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2005, 99 (03) : 395 - 401
  • [2] MARKERS OF PLATELET ACTIVATION IN CORONARY HEART-DISEASE PATIENTS
    NURDEN, AT
    MACCHI, L
    BIHOUR, C
    DURRIEU, C
    BESSE, P
    NURDEN, P
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1994, 24 : 42 - 45
  • [3] AFFAIRS OF THE HEART - CHOLESTEROL AND CORONARY HEART-DISEASE RISK
    SHEPHERD, J
    GAFFNEY, D
    PACKARD, CJ
    DISEASE MARKERS, 1991, 9 (02) : 63 - 71
  • [4] The relationship between the effect of pravastatin and risk factors for coronary heart disease in Japanese patients with hypercholesterolemia
    Ishikawa, Toshitsugu
    Mizuno, Kyoichi
    Nakaya, Noriaki
    Ohashi, Yasuo
    Tajima, Naoko
    Kushiro, Toshio
    Teramoto, Tamio
    Uchiyama, Shinichiro
    Nakamura, Haruo
    CIRCULATION JOURNAL, 2008, 72 (10) : 1576 - 1582
  • [5] REDUCTION IN SERUM-CHOLESTEROL WITH PRAVASTATIN IMPROVES ENDOTHELIUM-DEPENDENT CORONARY VASOMOTION IN PATIENTS WITH HYPERCHOLESTEROLEMIA
    EGASHIRA, K
    HIROOKA, Y
    KAI, H
    SUGIMACHI, M
    SUZUKI, S
    INOU, T
    TAKESHITA, A
    CIRCULATION, 1994, 89 (06) : 2519 - 2524
  • [6] CHOLESTEROL IN PATIENTS WITH CORONARY HEART-DISEASE - HOW LOW SHOULD WE GO
    RUBINS, HB
    JOURNAL OF GENERAL INTERNAL MEDICINE, 1995, 10 (08) : 464 - 471
  • [7] CONTRIBUTION OF HIGH SERUM-CHOLESTEROL TO PROGRESSION OF CORONARY ATHEROSCLEROSIS AND SUBSEQUENT CLINICAL EVENTS IN PATIENTS WITH CORONARY HEART-DISEASE
    ROSSOUW, JE
    RIFKIND, BM
    CORONARY ARTERY DISEASE, 1991, 2 (08) : 870 - 874
  • [8] Glucose-cholesterol interaction magnifies coronary heart disease risk for hypertensive patients
    Cohen, HW
    Hailpern, SM
    Alderman, MH
    HYPERTENSION, 2004, 43 (05) : 983 - 987
  • [9] LDL-C goal attainment with the addition of ezetimibe to on-going simvastatin treatment in coronary heart disease patients with hypercholesterolemia
    Brohet, C
    Banai, S
    Alings, AMW
    Massaad, R
    Davies, MJ
    Allen, C
    CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (04) : 571 - 578
  • [10] Radial Arterial Wave Reflection is Associated with the MEGA Risk Prediction Score, an Indicator of Coronary Heart Disease Risk, in Middle-Aged Men with Mild to Moderate Hypercholesterolemia
    Otsuka, Toshiaki
    Kawada, Tomoyuki
    Ibuki, Chikao
    Kusama, Yoshiki
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2010, 17 (07) : 688 - 694
123